Clinical trials in Hague – page 9

128 clinical trials in Hague, The Netherlands across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in the NetherlandsKlinischOnderzoek.nl

Hague at a glance

128

clinical trials

Research sites3

Quick filters

128 trials in Hague

Open in trial search

Sickle cell anaemia+1

Not recruiting

Study on Crizanlizumab for Adolescents and Adults with Sickle Cell Disease Experiencing Vaso-Occlusive Crises

InvestigationalNo placebo

Study on Crizanlizumab for Adolescents and Adults with Sickle Cell Disease Experiencing Vaso-Occlusive Crises

InvestigationalNo placebo

The Netherlands

Participants:0–17 years · 18–64 years · 65+ years
Substances:Crizanlizumab
Sponsor:Novartis Pharma AG

Contact Research Centre

Diffuse large B-cell lymphoma

Not recruiting

Study on the Safety and Effectiveness of Epcoritamab with R-CHOP for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Registered drugNo placebo

Study on the Safety and Effectiveness of Epcoritamab with R-CHOP for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Cyclophosphamide
Sponsor:AbbVie Deutschland GmbH & Co. KG

Contact Research Centre

Plasma cell myeloma

Not recruiting

Study Comparing Elranatamab and Lenalidomide for Patients with Newly Diagnosed Multiple Myeloma After Stem-Cell Transplantation

Registered drugNo placebo

Study Comparing Elranatamab and Lenalidomide for Patients with Newly Diagnosed Multiple Myeloma After Stem-Cell Transplantation

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Elranatamab
Sponsor:Pfizer Inc.

Contact Research Centre

B-cell lymphoma+1

Not recruiting

Study on Epcoritamab, Rituximab, and Lenalidomide for Adults with Untreated Follicular Lymphoma

Registered drugNo placebo

Study on Epcoritamab, Rituximab, and Lenalidomide for Adults with Untreated Follicular Lymphoma

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Cyclophosphamide
Sponsor:AbbVie Deutschland GmbH & Co. KG

Contact Research Centre

Heart failure with reduced ejection fraction

Not recruiting

Study on the Safety and Effectiveness of Tovinontrine for Adults with Chronic Heart Failure with Reduced Ejection Fraction

Investigational

Study on the Safety and Effectiveness of Tovinontrine for Adults with Chronic Heart Failure with Reduced Ejection Fraction

Investigational

The Netherlands

Participants:18–64 years · 65+ years
Substances:Tovinontrine
Sponsor:Cardurion Pharmaceuticals Inc.

Contact Research Centre

Mantle cell lymphoma

Not recruiting

Study of Zanubrutinib and Rituximab Compared to Bendamustine and Rituximab for Patients with Untreated Mantle Cell Lymphoma Ineligible for Stem Cell Transplant

Registered drugNo placebo

Study of Zanubrutinib and Rituximab Compared to Bendamustine and Rituximab for Patients with Untreated Mantle Cell Lymphoma Ineligible for Stem Cell Transplant

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Rituximab
Sponsor:BeOne Medicines AG

Contact Research Centre

Chronic lymphocytic leukaemia

Not recruiting

Study on Obinutuzumab and Venetoclax for Elderly Patients with Chronic Lymphocytic Leukemia Unfit for Standard Treatments

Registered drugNo placebo

Study on Obinutuzumab and Venetoclax for Elderly Patients with Chronic Lymphocytic Leukemia Unfit for Standard Treatments

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Obinutuzumab
Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Contact Research Centre

Bronchiectasis

Not recruiting

Study on the Effects of Itepekimab for Patients with Non-Cystic Fibrosis Bronchiectasis

Investigational

Study on the Effects of Itepekimab for Patients with Non-Cystic Fibrosis Bronchiectasis

Investigational

The Netherlands

Participants:18–64 years · 65+ years
Substances:Itepekimab
Sponsor:Sanofi-Aventis Recherche & Developpement

Contact Research Centre

Type IIa hyperlipidaemia

Not recruiting

Study on the Effectiveness of Enlicitide Chloride in Reducing Cardiovascular Events in Patients with Atherosclerotic Cardiovascular Disease

Investigational

Study on the Effectiveness of Enlicitide Chloride in Reducing Cardiovascular Events in Patients with Atherosclerotic Cardiovascular Disease

Investigational

The Netherlands

Participants:18–64 years · 65+ years
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Prostate cancer metastatic

Not recruiting

Study of talazoparib and enzalutamide combination in men with DDR gene mutated metastatic castration-sensitive prostate cancer

Registered drug

Study of talazoparib and enzalutamide combination in men with DDR gene mutated metastatic castration-sensitive prostate cancer

Registered drug

The Netherlands

Participants:18–64 years · 65+ years
Substances:Enzalutamide
Sponsor:Pfizer Inc.

Contact Research Centre

Transitional cell carcinoma

Not recruiting

Study of Disitamab Vedotin and Pembrolizumab for Patients with Untreated Advanced Urothelial Cancer Expressing HER2

Registered drugNo placebo

Study of Disitamab Vedotin and Pembrolizumab for Patients with Untreated Advanced Urothelial Cancer Expressing HER2

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Seagen Inc.

Contact Research Centre

Atrial fibrillation+3

Not recruiting

Study on Semaglutide for Achieving Sinus Rhythm in Patients with Obesity and Persistent Atrial Fibrillation

Investigational

Study on Semaglutide for Achieving Sinus Rhythm in Patients with Obesity and Persistent Atrial Fibrillation

Investigational

The Netherlands

Participants:18–64 years · 65+ years
Substances:Semaglutide
Sponsor:Rijnstate Ziekenhuis Stichting

Contact Research Centre

Other cities in the Netherlands

The busiest research cities in the country

All 103 cities in the Netherlands

Clinical research in Hague

What the registry says about research in the country

01 Leukemia Research

Innovative clinical trials focusing on Acute Myeloid Leukemia (AML) and associated conditions, evaluating targeted therapies in combination with standard treatments.

FLT3 Mutation Studies
Combination Therapy Approaches
Maintenance Treatment Protocols

Research aims to improve survival rates through personalized treatment strategies for newly diagnosed patients.

02 Lymphoma Studies

Comprehensive research on Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma, investigating novel therapeutic combinations and immunotherapy approaches.

High-Grade B-Cell Lymphoma Treatment
Immunotherapy Consolidation
Relapsed/Refractory Disease Management

Studies focus on improving disease-free survival rates using innovative treatment combinations.

03 Targeted Therapies

Advanced research into targeted therapeutic approaches for hematologic malignancies, combining conventional chemotherapy with novel agents.

Immunotherapy Integration
Consolidation Strategies
Risk-Adapted Treatment Approaches

Trials aim to establish more effective and personalized treatment protocols for high-risk patients.

Back to the Netherlands All countries